Hill Emily Luisa
Known title: Chief Financial OfficerCIK: 0001778279
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
PTC Therapeutics to Report Q3 2026 Earnings on Oct 29. PTC Therapeutics has announced it will release its third-quarter 2026 financial results on October 29, 2026. This upcoming report is the primary catalyst for the stock in the near term. The company's shares are currently trading below the average analyst price target, with the stock recently testing key support levels.
Transaction History
| REPL | ▼ Sell | Open Market | 9,256 | $132K | 8/17/2026 | View on chart |
| REPL | ▼ Sell | Open Market | 11,448 | $148K | 8/10/2026 | View on chart |
| REPL | ▼ Sell | Open Market | 7,812 | $40K | 5/18/2026 | View on chart |
| REPL | ▲ Buy | Grant | 50,000 | $0 | 4/1/2026 | View on chart |
| REPL | ▲ Buy | Grant | 60,000 | $0 | 12/19/2025 | View on chart |
| REPL | ▼ Sell | Open Market | 9,154 | $49K | 8/15/2025 | View on chart |
| REPL | ▼ Sell | Open Market | 2,535 | $20K | 5/20/2025 | View on chart |
| REPL | ▲ Buy | Grant | 45,000 | $0 | 4/1/2025 | View on chart |
| REPL | ▼ Sell | Open Market | 8,938 | $91K | 8/16/2024 | View on chart |
| REPL | ▲ Buy | Grant | 26,665 | $0 | 4/1/2024 | View on chart |
| REPL | ▲ Buy | Grant | 83,330 | $0 | 9/18/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 7,363 | $331K | 3/27/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 575 | $26K | 1/31/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 223 | $11K | 1/24/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 418 | $19K | 1/11/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 497 | $21K | 1/10/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 758 | $32K | 1/9/2023 | View on chart |
| PTCT | ▲ Buy | Grant | 19,500 | $0 | 1/5/2023 | View on chart |
| PTCT | ▼ Sell | Open Market | 7,910 | $299K | 3/31/2022 | View on chart |
| PTCT | ▼ Sell | Open Market | 553 | $22K | 2/1/2022 | View on chart |
| PTCT | ▼ Sell | Open Market | 211 | $8K | 1/25/2022 | View on chart |
| PTCT | ▼ Sell | Open Market | 800 | $31K | 1/7/2022 | View on chart |
| PTCT | ▲ Buy | Grant | 15,600 | $0 | 1/7/2022 | View on chart |
| PTCT | ▼ Sell | Open Market | 173 | $7K | 1/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Replimune Launches TUDRIQEV Amidst Mixed Analyst Views
Replimune Group has launched TUDRIQEV, marking a key step in its commercial strategy. Analysts are currently assessing the product's potential, with some suggesting a wait-and-see approach until market performance becomes clearer. The stock is trading near significant support levels, reflecting cautious sentiment as investors evaluate the new launch.
Replimune Launches TUDRIQEV Amidst Mixed Analyst Views. Replimune Group has launched TUDRIQEV, marking a key step in its commercial strategy. Analysts are currently assessing the product's potential, with some suggesting a wait-and-see approach until market performance becomes clearer. The stock is trading near significant support levels, reflecting cautious sentiment as investors evaluate the new launch.